First Horizon Advisors Inc. Purchases 2,134 Shares of GSK PLC Sponsored ADR $GSK

First Horizon Advisors Inc. increased its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 209.0% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 3,155 shares of the pharmaceutical company’s stock after acquiring an additional 2,134 shares during the quarter. First Horizon Advisors Inc.’s holdings in GSK were worth $121,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. HHM Wealth Advisors LLC increased its stake in GSK by 222.2% during the 1st quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company’s stock worth $26,000 after purchasing an additional 460 shares in the last quarter. Costello Asset Management INC acquired a new position in shares of GSK in the first quarter valued at approximately $31,000. SOA Wealth Advisors LLC. increased its position in shares of GSK by 252.1% during the second quarter. SOA Wealth Advisors LLC. now owns 845 shares of the pharmaceutical company’s stock worth $32,000 after acquiring an additional 605 shares in the last quarter. Richardson Financial Services Inc. raised its holdings in shares of GSK by 127.9% during the first quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company’s stock worth $33,000 after acquiring an additional 472 shares during the period. Finally, Cary Street Partners Investment Advisory LLC lifted its position in GSK by 525.9% in the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 1,014 shares of the pharmaceutical company’s stock valued at $39,000 after acquiring an additional 852 shares in the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Stock Down 1.0%

NYSE:GSK opened at $46.63 on Friday. GSK PLC Sponsored ADR has a twelve month low of $31.72 and a twelve month high of $47.21. The firm has a market capitalization of $94.78 billion, a price-to-earnings ratio of 13.17, a price-to-earnings-growth ratio of 1.90 and a beta of 0.50. The company has a quick ratio of 0.57, a current ratio of 0.87 and a debt-to-equity ratio of 1.07. The stock’s 50 day moving average price is $42.79 and its two-hundred day moving average price is $40.12.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, October 29th. The pharmaceutical company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.26 by $0.22. The company had revenue of $11.35 billion during the quarter, compared to the consensus estimate of $8.21 billion. GSK had a return on equity of 51.07% and a net margin of 17.16%.The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.50 EPS. GSK has set its FY 2025 guidance at 4.730-4.810 EPS. Equities research analysts expect that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 8th. Stockholders of record on Friday, November 14th will be given a $0.4171 dividend. This represents a $1.67 dividend on an annualized basis and a dividend yield of 3.6%. The ex-dividend date of this dividend is Friday, November 14th. GSK’s dividend payout ratio (DPR) is 46.05%.

Wall Street Analyst Weigh In

GSK has been the subject of a number of research reports. Jefferies Financial Group reiterated a “buy” rating on shares of GSK in a report on Monday, October 27th. Cfra set a $53.00 price objective on GSK in a report on Thursday, October 30th. Wall Street Zen raised GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 5th. Finally, Weiss Ratings raised GSK from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday, October 31st. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $42.58.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.